BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22977269)

  • 1. Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study.
    Schneider R; Schneider M; Reiners C; Schneider P
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3926-34. PubMed ID: 22977269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study.
    Wang S; Wang Y; Zhu L; He L; Lv M; Zhang H; Wang H; Zhang F; Lai Y; Li Y; Shan Z; Teng W
    Endocrine; 2023 Jan; 79(1):113-124. PubMed ID: 36089636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment.
    Mikosch P; Obermayer-Pietsch B; Jost R; Jauk B; Gallowitsch HJ; Kresnik E; Leb G; Lind P
    Thyroid; 2003 Apr; 13(4):347-56. PubMed ID: 12804103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression.
    Tournis S; Antoniou JD; Liakou CG; Christodoulou J; Papakitsou E; Galanos A; Makris K; Marketos H; Nikopoulou S; Tzavara I; Triantafyllopoulos IK; Dontas I; Papaioannou N; Lyritis GP; Alevizaki M
    Clin Endocrinol (Oxf); 2015 Feb; 82(2):197-204. PubMed ID: 25040693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy.
    Bin-Hong D; Fu-Man D; Yu L; Xu-Ping W; Bing-Feng B
    Endokrynol Pol; 2020; 71(1):15-20. PubMed ID: 31681976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
    Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
    Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
    Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
    Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
    J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T; Nery L; Hales I
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
    Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
    Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
    Kim MK; Yun KJ; Kim MH; Lim DJ; Kwon HS; Song KH; Kang MI; Baek KH
    Bone; 2015 Feb; 71():101-5. PubMed ID: 25445448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
    Sijanovic S; Karner I
    Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
    Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
    Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment.
    Eftekhari M; Asadollahi A; Beiki D; Izadyar S; Gholamrezanezhad A; Assadi M; Fard-Esfahani A; Fallahi B; Takavar A; Saghari M
    Hell J Nucl Med; 2008; 11(3):160-3. PubMed ID: 19081859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B; Puavilai G; Rajatanavin R
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density in treated at a young age for differentiated thyroid cancer after Chernobyl female patients on TSH-suppressive therapy receiving or not Calcium-D3 supplementation.
    Leonova TA; Drozd VM; Saenko VA; Mine M; Biko J; Rogounovitch TI; Takamura N; Reiners C; Yamashita S
    Endocr J; 2015; 62(2):173-82. PubMed ID: 25374130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
    López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
    Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone mineral density in patients on long-term therapy with levothyroxine].
    Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
    Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients.
    Mendonça Monteiro de Barros G; Madeira M; Vieira Neto L; de Paula Paranhos Neto F; Carvalho Mendonça LM; Corrêa Barbosa Lima I; Corbo R; Fleiuss Farias ML
    J Bone Miner Metab; 2016 Jul; 34(4):417-21. PubMed ID: 26056020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.